ATE444972T1 - ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR - Google Patents
ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTORInfo
- Publication number
- ATE444972T1 ATE444972T1 AT03725701T AT03725701T ATE444972T1 AT E444972 T1 ATE444972 T1 AT E444972T1 AT 03725701 T AT03725701 T AT 03725701T AT 03725701 T AT03725701 T AT 03725701T AT E444972 T1 ATE444972 T1 AT E444972T1
- Authority
- AT
- Austria
- Prior art keywords
- higf
- antibodies
- igf
- human
- ßinsulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002129046 | 2002-04-30 | ||
PCT/JP2003/005505 WO2003093317A1 (fr) | 2002-04-30 | 2003-04-30 | Anticorps pour facteur de croissance humain semblable a l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE444972T1 true ATE444972T1 (de) | 2009-10-15 |
Family
ID=29397291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03725701T ATE444972T1 (de) | 2002-04-30 | 2003-04-30 | ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR |
Country Status (9)
Country | Link |
---|---|
US (1) | US7438911B2 (de) |
EP (1) | EP1505075B1 (de) |
JP (1) | JP4335130B2 (de) |
AT (1) | ATE444972T1 (de) |
AU (1) | AU2003231554A1 (de) |
CA (1) | CA2483848C (de) |
DE (1) | DE60329589D1 (de) |
ES (1) | ES2333952T3 (de) |
WO (1) | WO2003093317A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4638870B2 (ja) | 2003-08-13 | 2011-02-23 | ファイザー・プロダクツ・インク | 修飾ヒトigf−1r抗体 |
WO2005018671A1 (ja) * | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | 癌転移阻害剤 |
WO2005028515A1 (ja) * | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
SI1979001T1 (sl) * | 2005-12-13 | 2012-08-31 | Medimmune Ltd | Vezni proteini specifiäśno za inzulinu podobne rastne faktorje in njih uporaba |
RS52357B (en) | 2005-12-13 | 2012-12-31 | Medimmune Limited | BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE |
BRPI0709481A2 (pt) * | 2006-04-07 | 2011-07-19 | Government Of The Us Secretary Dept Of Health And Human Services | anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco |
WO2008152422A2 (en) * | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
JP5734180B2 (ja) * | 2008-05-09 | 2015-06-17 | ダイアックス コーポレーション | Igf−ii/igf−iie結合タンパク質 |
KR20110016958A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | ***素e2双重可变结构域免疫球蛋白及其用途 |
EP2349329A4 (de) * | 2008-10-14 | 2012-10-31 | Dyax Corp | Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose |
PT2376116E (pt) * | 2008-12-12 | 2016-02-24 | Boehringer Ingelheim Int | Anticorpos anti-igf |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
RU2012112550A (ru) * | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
IN2015DN02826A (de) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
AU2010303383B2 (en) * | 2009-10-07 | 2014-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011081164A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 抗cd27抗体 |
MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2012061374A2 (en) * | 2010-11-02 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
CN102520190B (zh) * | 2011-12-15 | 2014-03-05 | 中国人民解放军总医院 | 一种人***ⅱ酶联免疫分析检测试剂盒 |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
EP3662928A1 (de) | 2014-04-10 | 2020-06-10 | OBI Pharma Inc. | Antikörper, die an tumor assoziierte kohlehydrat-antigene binden, pharmazeutische zusammensetzungen und deren anwendung |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000831A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
AU1232188A (en) * | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
CA2058041A1 (en) * | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
EP0700994A1 (de) * | 1994-03-23 | 1996-03-13 | Japan Clinical Laboratories | Monoklonale anti-igf-i antikörper |
WO2005018671A1 (ja) * | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | 癌転移阻害剤 |
-
2003
- 2003-04-30 DE DE60329589T patent/DE60329589D1/de not_active Expired - Lifetime
- 2003-04-30 AU AU2003231554A patent/AU2003231554A1/en not_active Abandoned
- 2003-04-30 US US10/513,148 patent/US7438911B2/en not_active Expired - Fee Related
- 2003-04-30 ES ES03725701T patent/ES2333952T3/es not_active Expired - Lifetime
- 2003-04-30 CA CA2483848A patent/CA2483848C/en not_active Expired - Fee Related
- 2003-04-30 WO PCT/JP2003/005505 patent/WO2003093317A1/ja active Application Filing
- 2003-04-30 JP JP2004501456A patent/JP4335130B2/ja not_active Expired - Fee Related
- 2003-04-30 EP EP03725701A patent/EP1505075B1/de not_active Expired - Lifetime
- 2003-04-30 AT AT03725701T patent/ATE444972T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1505075A4 (de) | 2006-06-21 |
CA2483848A1 (en) | 2003-11-13 |
US7438911B2 (en) | 2008-10-21 |
JPWO2003093317A1 (ja) | 2005-09-08 |
DE60329589D1 (de) | 2009-11-19 |
EP1505075B1 (de) | 2009-10-07 |
US20060165695A1 (en) | 2006-07-27 |
WO2003093317A1 (fr) | 2003-11-13 |
AU2003231554A1 (en) | 2003-11-17 |
JP4335130B2 (ja) | 2009-09-30 |
ES2333952T3 (es) | 2010-03-03 |
CA2483848C (en) | 2012-08-21 |
EP1505075A1 (de) | 2005-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE444972T1 (de) | ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
MX2009005597A (es) | Miembros de enlace para interleucina 6. | |
MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
HK1108000A1 (en) | Anti-ox4ol antibodies | |
EP2535353A8 (de) | An hGM-CSF bindende monoklonale Antikörper und medizinische Zusammensetzungen damit | |
ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
ATE536376T1 (de) | Humanes bindungsmolekül gegen cd1a | |
EA200900345A1 (ru) | Замещенные ациланилиды и способы их применения | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
TW200716612A (en) | Pyrimidine compounds | |
MX2009006066A (es) | Tratamiento de cerdos con el antigeno pcv. | |
MX338247B (es) | Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. | |
WO2007025977A8 (en) | Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis | |
EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
ATE412414T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
ATE520032T1 (de) | Differentielle cytokinexpression bei einer menschlichen krebserkrankung | |
BR0307629A (pt) | Métodos e composições para tratar condições hiperproliferativas | |
ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
WO2010036567A3 (en) | Harmine compounds for promoting bone growth | |
HK1097762A1 (en) | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients | |
TW200628168A (en) | Use of organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |